InMode reported Q2 revenue of $95.589 million, topping the $93 million IBES estimate, as U.S. aesthetic practices continue steady adoption of its RF microneedling (Morpheus8) and radiofrequency platforms. The beat reflects sustained demand for energy-based devices in the post-pandemic normalization of medspa traffic and pricing.